PT  - JOURNAL ARTICLE
AU  - Bankhead, Charles
ED  - Jett, James R.
TI  - Advances in NSCLC
DP  - 2011 Sep 01
TA  - MD Conference Express
PG  - 20--21
VI  - 11
IP  - 4
4099  - http://mdc.sagepub.com/content/11/4/20.short
4100  - http://mdc.sagepub.com/content/11/4/20.full
AB  - The era of targeted therapy has arrived for lung cancer and has made an unprecedented impact on outcomes, including survival. Choosing therapy on the basis of mutation testing has dramatically increased survival expectations from a few months with conventional chemotherapy to as much as 3 years with targeted agents.